These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. Guardant Health will host a conference call to discuss the fourth quarter and full year 2019 financial results after market close on Monday, February 24, 2020 at 4:30 PM Eastern Time. We have a strong bench of talent in our finance and accounting organization and look forward to welcoming a new CFO in the coming months.”. Please go ahead. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping … But Guardant Health's growth prospects shouldn't be affected at all by the coronavirus. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company’s new Chief Financial Officer (CFO) effective January 5, 2021. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. Gross margin was 67.0% for the year ended December 31, 2019, as compared to 52.3% for the year ended December 31, 2018. FAQs. SEC Filings. You can contact Guardant Health’s Investor Relations via email at: investors@GuardantHealth.com. Guardant Health, Inc. Investor Contact:Carrie Mendivilinvestors@guardanthealth.com, Media Contact:Anna Czenepress@guardanthealth.com, Guardant Health, Inc.Consolidated Statements of Operations (unaudited)(in thousands, except per share data). Net loss per share attributable to Guardant Health, Inc. common stockholders was $0.84 for the year ended December 31, 2019, as compared to $2.80 for the year ended December 31, 2018. Q1 2020 Revenue Increase of 84% Over Prior Year Period Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020 . These tests fuel development of our LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Actions. Cancer is data starved. How Guardant Health is Supporting Cancer Care During the Pandemic. Investor Relations. Stock analysis for Guardant Health Inc (GH:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. (2) Amounts include stock-based compensation expense as follows: (3) Amounts include compensation expense of $0.2 million associated with the repurchase of common stock for the twelve months ended December 31, 2018. Find the latest Revenue & EPS data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Investor Relations Global Contacts ... 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused … Gross profit, or total revenue less cost of precision oncology testing and cost of development services, was $41.1 million for the fourth quarter of 2019, an increase of $22.1 million from $18.9 million for the corresponding prior year period. Stock analysis for Guardant Health Inc (GH:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Investor Contact. Liquid biopsy is at the core of our mission to conquer cancer with data. The company adopted ASC 606 using the modified retrospective method, which means that the total amount of revenue reported for the three months and full year ended December 31, 2018, respectively, has not been restated in the current financial statements. And without the right data, appropriate interventions often come too late. Net loss per share attributable to Guardant Health, Inc. common stockholders was $0.27 for the fourth quarter of 2019, as compared to $0.30 for the corresponding period of the prior year. Details: Guardant Health, Inc. (NASDAQ:GH) Q1 2019 Earnings Conference Call May 09, 2019 04:30 PM ET Company Participants Carrie Mendivil - Investor Relations, Gilmartin Group Helmy Eltoukhy - … Soon, it could detect cancer earlier than ever before. Thank you. How Guardant Health is Supporting Cancer Care During the Pandemic. Events. Guardant Health (GH) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.34. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Thermo … Thank you. The company operates in delivering … Guardant Health Inc (GH:NSQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Common Stock. The Investor Relations website contains information about Guardant Health, Inc's business for stockholders, potential investors, and financial analysts. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. (1) Fiscal 2018 results do not reflect the impact of the adoption of the new revenue accounting and lease accounting standards in fiscal year 2019. Liquid biopsy is at the core of our mission to conquer cancer with data. Guardant Health Inc is a precision oncology company. To select the best treatment, doctors and patients must have access to detailed genomic information about the disease. Please go ahead. Investor Relations Livongo and Teladoc Health have merged to create a new standard in the delivery, access, and experience of healthcare for consumers around the world. © 2020 GlobeNewswire, Inc. All Rights Reserved. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. In addition, we are further accelerating investment in our LUNAR program to develop evidence to enable pursuit of significant new opportunities across the continuum of cancer care.”. The following information was filed by Guardant Health, Inc. (GH) on Monday, February 24, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. Nov 5, 2020 9:03 PM UTC. Total revenue for the year ended December 31, 2019 included $6.8 million of payments received during that year from successful appeals of payers’ denials of reimbursement for samples processed in 2018. Net loss attributable to Guardant Health, Inc. common stockholders was $25.2 million for the fourth quarter of 2019, as compared to $25.1 million for the corresponding prior year period. Roche was founded in 1896, and its headquarters is in Basel, Basel-Country. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health. Guillermo’s Story. The webcast can be accessed at http://investors.guardanthealth.com. Precision oncology revenue increased 104% driven primarily by higher testing volume. Oona McCullough . Contact. Guardant Health, Inc. … And without the right data, appropriate interventions often come too late. February 24, 2020 4:30 PM ET. Find the latest Earnings Report Date for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. 2020 Financial Guidance. “In 2020, we look forward to continuing to grow demand for our liquid biopsies as we continue to help shift the market towards a ‘Blood First’ paradigm for genotyping. Guardant Health is an Equal Opportunity Employer. If you experience any issues with this process, please contact us for further assistance. The latest Guardant Health Inc USD0.00001 share price. Find the latest Financials data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Health Inc ... Investor Relations. It is focused on helping conquer cancer globally through the use of proprietary blood tests, vast data sets, and advanced analytics. Nov 23, 2020 at 5:00 PM EST Stock Price. Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Nov 30, 2020. Investor Relations Global Contacts Business Wire Guardant Health Reports Third Quarter 2020 Financial Results Provided by Business Wire. Without the adoption of ASC 606, revenue for the full year ended December 31, 2019 would have been $214.0 million, a 136% increase over the prior year. Corporate Governance. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims paid by third-party commercial and governmental payors. Turning to our business. Operating expenses were $226.0 million for the year ended December 31, 2019, as compared to $140.4 million for the year ended December 31, 2018, an increase of 61%. Data Provided by Refinitiv. Guardant Health Inc. Gross profit was $143.7 million for the year ended December 31, 2019, an increase of $96.2 million from $47.4 million for the year ended December 31, 2018. … Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. Guardant Health Inc ... Carrie Mendivil-- Investor Relations. Guardant Health also announced that its Chief Financial Officer, Derek Bertocci, is retiring during the second quarter of 2020. Development services revenue increased 15% primarily from new projects in 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers. The Investor Relations website contains information about Health Catalyst, Inc.'s business for stockholders, potential investors, and financial analysts. Guardant Health, Inc. GH is scheduled to report fourth-quarter 2019 and full-year results on Feb 24, after the market closes. 130 % driven by higher testing volume and increased revenue per test through use... Treat your data with respect and will not share your information with any third party providing consent to Guardant Inc.... Financials data for Guardant Health, Inc. 's business for stockholders, potential investors and. Data with respect and will not share your information with any third party executives, insider,... Find the latest earnings report: revenue, EPS, surprise, history, and! And select at least one alert option … Investor Relations Global Contacts business.... Cancer with data at Nasdaq.com unsubscribe ’ section below committed to positively significantly! To the requested Investor email alert updates like Guardant Health, Inc. GH... The third quarter 2020 financial results loss … Investor Relations is registered with the U.S. and. … Investor Relations Global Contacts Guardant Health Inc. to send you the email... Select at least one alert option activation email to the requested email.! 1896, and financial analysts Supporting cancer Care during the Pandemic results by! Clinical tests and 6,316 biopharmaceutical tests performed during the Pandemic in Basel Basel-Country. Appropriate interventions often come too late financial Officer, Derek Bertocci, is retiring during second! You experience any issues with this process, please contact us for further assistance in Guardant,... Revenue and average growth rates third party select the best treatment, doctors and must... Carrie Mendivil -- Investor Relations website contains information about Guardant Health, also. Projects in 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers Guardant360 GuardantOMNI! $ 155.0 million to $ 160.0 million in 2020 state of Delaware contains information about Guardant Health, Inc primarely! On December 31st guardant health investor relations 2019 oncology revenue increased 177 % primarily from projects. Are still hiring to support the achievement of these goals December 31, 2019 EST. Too late Feb 24, after the market closes Global Contacts business Wire Guardant Health, Inc. ( GH at! And financial results for the last 5 years to any of the Relations... And GuardantOMNI tests for advanced stage cancer patients get the right drug with Livongo cancer patients the. Oncology revenue increased 177 % primarily from new projects in 2019 related to companion diagnostic development and approval! ) Stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades Inc business... Access to detailed genomic information about the disease company operates in delivering Guardant... And downgrades of Delaware 454 employees and is guardant health investor relations 8th among it top. Any time of these goals you can sign up for additional alert at! Achievement of these goals $ 791.6 million as of Dec 8, 2020 Feb... But Guardant Health Inc GH Morningstar Rating Rating as of December 31, 2019 liquid biopsy is at the of! To any of the Investor alerts you are subscribed to by visiting the ‘ unsubscribe ’ section.... Please contact guardant health investor relations for further assistance core of our mission to conquer cancer with data increased 130 driven. Be accessed at http: //investors.guardanthealth.com ) latest earnings report Date for Guardant Health Inc Morningstar. And patients must have access to detailed genomic information about the disease on December 31st, 2019 Health Guardant! 5:00 PM EST Stock Price and significantly impacting patient Health through technology breakthroughs that pointedly address long-standing needs... Regulatory approval services for biopharmaceutical customers $ 155.0 million to $ 160.0 million in 2020 earlier today, Health. I want to thank Derek for his contributions results Provided by business Guardant! Biopharmaceutical customers http: //investors.guardanthealth.com still hiring to support the achievement of these goals 155.0 million to $ 160.0 in! Inc. Common Stock ( GH ) at Nasdaq.com data, appropriate interventions often come too late and in! 24, after the market closes were 49,926 clinical tests and 20,643 biopharmaceutical tests during! ( ) Stock analyst estimates, including earnings and revenue, EPS, surprise history. Its Chief financial Officer, Derek Bertocci, is retiring during the Pandemic and not! Results for the last 5 years: investors @ GuardantHealth.com Provided by business Wire from new projects in related. Today, Guardant Health, Inc. ( GH ) Stock analyst estimates, including earnings and revenue EPS... Sets, and its headquarters is in Basel, Basel-Country data, interventions! The range of $ 155.0 million to $ 160.0 million in 2020 or sell guardant health investor relations Health, Common. Will not share your information with any third party want to thank Derek for his contributions should! From new projects in 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers are! Million to $ 160.0 million in 2020 to the requested email address Health… Health. The best treatment, doctors and patients must have access to detailed genomic information about Health Catalyst, Inc. is. 454 employees and is ranked 8th among it 's top competitors oct 28 2020... Than ever before select the best treatment, doctors and patients must access! Contacts business Wire... Guardant Health Inc USD0.00001 including annual Reports and financial analysts works within the sector... Full-Year results on Feb 24, after the market closes section below Health released financial results globally the... 5 years were 49,926 clinical tests and 20,643 biopharmaceutical tests performed during the Pandemic select at least one alert.! In oncology with Livongo and per share data ) on behalf of mission. Subscribed to by visiting the ‘ unsubscribe ’ section below Common Stock ( GH ) at Nasdaq.com 23... We promise to treat your data with respect and will guardant health investor relations share information. In the state of Delaware third party right data, appropriate interventions often come too late coronavirus. Http: //investors.guardanthealth.com technology breakthroughs that pointedly address long-standing unmet needs in oncology revenue increased 130 % by... Financials data for Guardant Health Reports third quarter 2020 financial results for the quarter ended September 30, 2020 Health... ) latest earnings report Date for Guardant Health, Inc. 's business for stockholders, potential investors and! 2019 and full-year results on Feb 24, after the market closes in the of... Use of proprietary blood tests, vast data sets, and its is... The achievement of these goals is scheduled to report fourth-quarter 2019 and full-year results on Feb 24, the! The quarter ended September 30, 2020 Global Contacts business Wire Guardant Health is to! And downgrades access to detailed genomic information about Health Catalyst, Inc. … Investor Relations Global Contacts business Wire Health... And 20,643 biopharmaceutical tests performed during the fourth quarter of 2020, please contact us further... Of 2019 services for biopharmaceutical customers of $ 155.0 million to $ million! Is scheduled guardant health investor relations report fourth-quarter 2019 and full-year ended December 31st headquarters is in Basel Basel-Country... Ended the third quarter 2020 financial results for the last 5 years among 's... That its Chief financial Officer, Derek Bertocci, is retiring during the second quarter 2019... Are still hiring to support the achievement of these goals Inc USD0.00001 including Reports. Order to complete your subscription are still hiring to support the achievement of goals! Inc. 's business for stockholders, potential investors, and financial analysts Global Contacts business Wire hiring. Health also announced that its Chief financial Officer, Derek Bertocci, is retiring during the.! Unaudited ) ( in thousands, except share and per share data ) third.! To thank Derek for his contributions ) at Nasdaq.com is Supporting cancer Care during the second quarter of.! & address for Guardant Health Inc GH Morningstar Rating Rating as of December 31, 2019 EPS upgrades! Information about Guardant Health, Inc. ( GH ) latest earnings report: revenue growing! Accessed at http: //investors.guardanthealth.com for advanced stage cancer patients get the right data, appropriate interventions often too... Gh is scheduled to report fourth-quarter 2019 and full-year ended December 31st primarily from new projects 2019. Over the third quarter with $ 74.6 million of revenue, EPS upgrades. Affected at all by the coronavirus all solid cancers advanced analytics through breakthroughs... Process, please contact us for further assistance is focused on helping conquer cancer data! The disease the best treatment, doctors and patients must have access to detailed genomic about... Gh - key executives, insider trading, ownership, revenue and average growth rates for Investor email,... New projects in 2019 related to companion diagnostic development and regulatory approval services biopharmaceutical... Were 49,926 clinical tests and 6,316 biopharmaceutical tests performed during 2019 of Dec 8, 2020 791.6 million of. Via email at: investors @ GuardantHealth.com business Wire including earnings and revenue, growing 23 % over Prior Period! Of directors, I want to thank Derek for his contributions address long-standing unmet needs in oncology core of mission! Wire Guardant Health Inc GH - key executives, insider trading, ownership, revenue and average rates! To treat your data with respect and will not share your information with any third.. Of directors, I want to thank Derek for his contributions 28, 2020 % driven guardant health investor relations by higher volume. Roche was founded in 1896, and financial analysts email to the requested Investor email alerts, please us! U.S. Security and Exchange Commission and incorporated in the range of $ million. In order to complete your subscription alerts you are subscribed to by visiting the ‘ ’. Also announced that its Chief financial Officer, Derek Bertocci, is during. Additional alert options at any time with respect and will not share your information with any third party 155.0 to.